NASDAQ:KNSA Kiniksa Pharmaceuticals International (KNSA) Stock Price, News & Analysis $76.27 -0.21 (-0.27%) Closing price 04:00 PM EasternExtended Trading$76.50 +0.23 (+0.31%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kiniksa Pharmaceuticals International Stock (NASDAQ:KNSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KNSA alerts:Sign Up Key Stats Today's Range$76.14▼$78.5950-Day Range$60.94▼$81.0352-Week Range$35.20▼$82.94Volume576,541 shsAverage Volume450,443 shsMarket Capitalization$5.95 billionP/E Ratio78.63Dividend YieldN/APrice Target$87.38Consensus RatingModerate Buy Company Overview Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs. Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for the maintenance of remission in cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome. The product is also approved for the treatment of deficiency of interleukin-1 receptor antagonist, a rare inherited inflammatory disorder. Founded in 2015, Kiniksa is headquartered in Hamilton, Bermuda, and conducts its commercial, clinical and research activities through operations serving the United States and other international markets. The company was co-founded by Sanjiv Patel, who serves as president and chief executive officer. In addition to ARCALYST, Kiniksa has pursued a pipeline of investigational therapies intended to address autoimmune, inflammatory and cardiovascular diseases.AI Generated. May Contain Errors. Read More Kiniksa Pharmaceuticals International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreKNSA MarketRank™: Kiniksa Pharmaceuticals International scored higher than 80% of companies evaluated by MarketBeat, and ranked 172nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingKiniksa Pharmaceuticals International has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialKiniksa Pharmaceuticals International has a consensus price target of $87.38, representing about 14.6% upside from its current price of $76.27.Amount of Analyst CoverageKiniksa Pharmaceuticals International has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kiniksa Pharmaceuticals International's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth51.09% Earnings GrowthEarnings for Kiniksa Pharmaceuticals International are expected to grow by 51.09% in the coming year, from $1.37 to $2.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals International is 78.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals International is 78.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.26.Price to Book Value per Share RatioKiniksa Pharmaceuticals International has a P/B Ratio of 10.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals International's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.11% of the float of Kiniksa Pharmaceuticals International has been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 8.69.Change versus previous monthShort interest in Kiniksa Pharmaceuticals International has recently decreased by 11.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiniksa Pharmaceuticals International does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals International does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.01 News SentimentKiniksa Pharmaceuticals International has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kiniksa Pharmaceuticals International this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Kiniksa Pharmaceuticals International to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $668,472.00 in company stock.Percentage Held by Insiders51.98% of the stock of Kiniksa Pharmaceuticals International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals International's insider trading history. Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNSA Stock News HeadlinesBiopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue BeatSeptember 11 at 1:00 AM | investors.comKiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare ConferenceSeptember 4, 2026 | globenewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 11 at 1:00 AM | Altimetry (Ad)Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth ConferenceAugust 7, 2026 | globenewswire.comKiniksa Pharmaceuticals International, plc 2026 Q2 - Results - Earnings Call PresentationJuly 31, 2026 | seekingalpha.comCould Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?July 29, 2026 | finance.yahoo.comWhy Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing PipelineJuly 29, 2026 | finance.yahoo.comKiniksa Pharmaceuticals International, plc GAAP EPS of $0.30 beats by $0.01, revenue of $243.6M beats by $17.14MJuly 28, 2026 | seekingalpha.comSee More Headlines KNSA Stock Analysis - Frequently Asked Questions How have KNSA shares performed this year? Kiniksa Pharmaceuticals International's stock was trading at $41.25 on January 1st, 2026. Since then, KNSA shares have increased by 84.9% and is now trading at $76.27. How were Kiniksa Pharmaceuticals International's earnings last quarter? Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced its quarterly earnings data on Tuesday, July, 28th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.00. The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a trailing twelve-month return on equity of 13.65%. Read the conference call transcript. When did Kiniksa Pharmaceuticals International IPO? Kiniksa Pharmaceuticals International (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals International's major shareholders? Kiniksa Pharmaceuticals International's top institutional shareholders include California State Teachers Retirement System (3.49%), Braidwell LP (0.24%), Squarepoint Ops LLC (0.18%) and Financial Enhancement Group LLC (0.04%). Insiders that own company stock include John F Paolini, Sanj K Patel, Michael R Megna, Eben Tessari, Thomas Malley, Barry D Quart, Mark Ragosa, Ross Moat and G Bradley Cole. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals International? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiniksa Pharmaceuticals International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals International investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings7/28/2026Today9/11/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KNSA's financial health is in the Green zone, according to TradeSmith. KNSA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KNSA CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees366Year Founded2015Price Target and Rating Average Price Target for Kiniksa Pharmaceuticals International$87.38 High Price Target$107.00 Low Price Target$60.00 Potential Upside/Downside+14.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.97 Trailing P/E Ratio78.63 Forward P/E Ratio55.67 P/E GrowthN/ANet Income$59.01 million Net Margins9.59% Pretax Margin13.59% Return on Equity13.65% Return on Assets10.09% Debt Debt-to-Equity RatioN/A Current Ratio3.90 Quick Ratio3.49 Sales & Book Value Annual Sales$677.56 million Price / Sales8.78 Cash Flow$0.79 per share Price / Cash Flow96.35 Book Value$7.44 per share Price / Book10.25Miscellaneous Outstanding Shares78,020,000Free Float37,467,000Market Cap$5.95 billion OptionableOptionable Beta0.09 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:KNSA) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
